PDI Reports 2009 Third Quarter Financi... (er 2009 For the quarter ended Septe...)

PDI Reports 2009 Third Quarter Financial Results

Date:11/5/2009

er 2009

For the quarter ended September 30, 2009, net revenue totaled $21.0 million, compared to $24.5 million in the same period last year. Revenue in the Sales Services segment for the third quarter of 2009 was $17.8 million, compared to $20.0 million in the same period of 2008. While Sales Services has gained revenue as a result of new contracts and the expansion of existing contracts, these gains were more than offset by lost revenue from the internalization of a contract sales force by a long-term client and the expiration or termination of other sales force arrangements in effect during 2008. Revenue in the Marketing Services segment for the third quarter of 2009 was $5.1 million compared to $4.5 million in 2008. A 30% increase in our Pharmakon business unit due to an increase in the number of projects was partially offset by a decrease in revenue from closing the VIM business unit in 2009.

Gross profit for the third quarter of 2009 was $6.9 million compared to $0.4 million in the same period last year. Gross profit for the Sales Services segment increased to $4.3 million from $2.8 million last year and gross profit in the Marketing Services segment increased to $2.4 million from $1.7 million in the year ago period. The impact on gross profit of lower revenue in the Sales Services segment was more than offset by lower operating costs, in large part resulting from the Company's cost savings initiatives as well as the recognition of higher performance related fees in 2009. The increase in gross profit in the Marketing Services segment was primarily attributable to higher revenue from our Pharmakon business unit. The Company's third quarter 2008 gross profit was negatively impacted by $4.1 million from the execution of the product commercialization agreement which was mutually terminated in the second quarter of 2009.

Total operating expenses for the third quarter of 2009 were $11.4 million compared to $10.0 million in t
'/>"/>

SOURCE PDI, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine technology :

1. CareFusion Reports First Quarter Results, Raises Full-Year Outlook
2. Symmetry Medical Reports Third Quarter 2009 Financial Results
3. NxStage(R) Reports Third Quarter 2009 Financial Results and Raises Revenue Guidance for Fiscal 2009
4. GSI Group Inc. Announces NASDAQ Delisting and Reports Progress on Revenue Recognition Review and Preliminary Third Quarter 2009 Bookings and Cash Balance
5. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
6. HeartWare International Reports Third Quarter Revenues of $7.5 Million
7. Varian, Inc. Reports Fourth Quarter 2009 Results
8. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
9. Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate Update
10. Cambrex Reports Third Quarter 2009 Results
11. Regeneron Reports Third Quarter 2009 Financial and Operating Results

Post Your Comments:

(Date:11/23/2009)...exas,Nov.23/PRNewswire-FirstCall/--WoundManagement...rowingproviderofspecialtymedicalproducts,announced...edacomprehensivemanagementbusinessupdatetoillustra... Q32009salesincreased33.5%to$102,926vs.Q32008sales...creasedto$3,327,892vs.Q32008shareholderequityof$(3...

(Date:11/23/2009)...S,Nov.23/PRNewswire/--AMDLASERSannouncedthisweekth...ionbypartneringwithprestigiousindustry-leaderDr.La...ERS,willbetheexclusivesofttissuediodelaserusedduri...rgetedtothetop2%ofdentists. ,, (Photo: http://w..., "ItiswithgreatpleasurethatIproudlyannounceourpa...

(Date:11/23/2009)...NCISCO,Calif.,Nov.23/PRNewswire-FirstCall/--Anesiv...eandDr.DavidC.U,PrichardhaveagreedtojointheAnesiva...rgerbetweenAnesivaandArcionTherapeutics.Completion...akeplaceatthepreviouslyannouncedAnesiva2009AnnualM...0a.m.PSTat400OysterPoint,Suite107A,SouthSanFrancis...

Breaking Medicine Technology:Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 2 Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 3 Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 4 Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 5 AMD LASERS Announces New Partnership with Dr. Larry Rosenthal and Aesthetic Advantage 2 Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 2 Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 3 Colorado Companies Team Up With U S Fish 26amp 3B Wildlife Service to Protect Black Footed Ferret 14744 1 Colorado Companies Team Up With U S Fish 26amp 3B Wildlife Service to Protect Black Footed Ferret 14744 2 Helix BioPharma Corp Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha 2b in Patients With Ano Genital Warts 6036 1 Helix BioPharma Corp Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha 2b in Patients With Ano Genital Warts 6036 2 Helix BioPharma Corp Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha 2b in Patients With Ano Genital Warts 6036 3 Helix BioPharma Corp Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha 2b in Patients With Ano Genital Warts 6036 4 Helix BioPharma Corp Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha 2b in Patients With Ano Genital Warts 6036 5 Helix BioPharma Corp Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha 2b in Patients With Ano Genital Warts 6036 6 Federal stimulus funds support studies geared to improving HIV care and prevention 60794 1 Federal stimulus funds support studies geared to improving HIV care and prevention 60794 2

[0] Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update [0] AMD LASERS Announces New Partnership with Dr. Larry Rosenthal and Aesthetic Advantage [0] Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger

... Shows R84, the Selective Human Anti-VEGF Antibod...fitech, Is Equivalent to Avastin in Inhibiting Gro...ical Breast Cancer Model -- -- R84 Is Being Ad...ON and TUSTIN, Calif., Nov. 13 Peregrine,Pharmace...opharmaceutical,company developing targeted monocl...

...AX) today reported financial results for the third... recent accomplishments and upcoming,milestones. N... equivalent,of $0.15 loss per share, compared with...08 loss per share in the third quarter of 2006. F...ompany reported a,net loss of $25.5 million or $0....

Other Medicine Technology:New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models 2 New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models 3 New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models 4 New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models 5 Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 2 Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 3 Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 4 Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 5 Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 6

New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs

(Date:11/23/2009)...ATBORO,Pa.,Nov.23/PRNewswire-FirstCall/--InfoLogix...nterprisemobilitysolutionsforthehealthcareandcomme...ePresidentofManagedServicesatSiemensHealthServices...hcareServices. ,, (Logo: http://www.newscom.com...residentofStrategicHealthcareServicesforInfoLogix,...

(Date:11/23/2009)...uarters of cancer patients and survivors treated w...s that often become chronic conditions, hindering ...cientists at the University of Rochester Medical C...hey experienced sleep troubles at nearly three tim... was more prevalent in younger patients and those ...

(Date:11/23/2009)...es saw their odds drop by 63 percent with moderate...Nov. 23 (HealthDay News) -- Moderate-to-high inten...may help reduce stroke risk in older men but not i...ed almost 3,300 men and women, average age 69, in ...During that time, there were 238 strokes among the...

(Date:11/23/2009)...nts up weaknesses of drug approval process in Unit...ov. 23 (HealthDay News) -- Problems with the popul...for heart attack, stroke and death, were known for... the market in 2004, a new report says. , Cont...., dangerous side effects were evident in 2000, a ...

(Date:11/23/2009)... SayscuttingMedicaretofinance"reform"isamoraloutra.../--WhiletheSenateDemocratsmovedforwardtobeginthede...eSafe,a400,000supporterstronggrassrootssenioradvoc...irbullhornstoprotestthemassivecutstoMedicare.Retir...gthefocusshifttoissuesliketaxes,abortion,andimmigr...

Breaking Medicine News(10 mins):Health News:Jim Way, Former Vice President at Siemens Health Services, Joins InfoLogix, Inc. as Vice President of Strategic Healthcare Services 2 Health News:Jim Way, Former Vice President at Siemens Health Services, Joins InfoLogix, Inc. as Vice President of Strategic Healthcare Services 3 Health News:Insomnia prevalent among cancer patients who receive chemotherapy 2 Health News:Vigorous Exercise Cuts Stroke Risk for Men, Not Women 2 Health News: Vioxx Problems Known Years Before Recall 2 Health News: Vioxx Problems Known Years Before Recall 3 Health News: Vioxx Problems Known Years Before Recall 4 Health News:RetireSafe Calls on Seniors to Grab their Bullhorns to Save Medicare from Rationed Care 2

[0] Jim Way, Former Vice President at Siemens Health Services, Joins InfoLogix, Inc. as Vice President of Strategic Healthcare Services [0] Insomnia prevalent among cancer patients who receive chemotherapy [1] Vigorous Exercise Cuts Stroke Risk for Men, Not Women [0] Vioxx Problems Known Years Before Recall [1] RetireSafe Calls on Seniors to Grab their Bullhorns to Save Medicare from Rationed Care

...s available in Spanish . , The autistic disord... by Dr. Leo Kanner of the Johns Hopkins Hospital (...tism. At the same time an Austrian scientist, Dr. ...rmal language function. Today, both disorders are ...

...usan G. Komen for the Cure(R), the,leader of the g...ization,the Susan G. Komen for the Cure Advocacy A...ttendees of the Republican National Convention,abo...com.com/cgi-bin/prnh/20070122/NYM084LOGO ), Komen...

...ncer Chronicles Film Festival awards prizes to top..., Sept. 1 Chrigu from Switzerland has been,awarde...ncer Chronicles,Film Festival at a ceremony in Gen...Story, The Children of Avenir (Morocco),for Best O...

...Aug. 31 Elbit Imaging Ltd.,(Nasdaq: EMITF ) ("EI...r the,second quarter of 2008., Profit for the sec...approximately US$ 16.7 million) of which profit of...llion) is,attributable to minority interest, compa...

.... - The fight against the liver disease hepatitis ...ith more than 150 million people currently infecte...sty side effects and often falling short of a cure...cess that in lab testing could be effectively targ...

...l but significant reduction in deaths; parallel st...cial effect. , , SUNDAY, Aug. 31 (HealthDa...rated fatty acids -- the kind found in fish oil --...effect in a parallel heart failure trial. , "This ...

The first autism disease genes Komen Travels to Republican Convention to Raise Awareness of Breast Cancer Issues Chrigu Wins Grand Prize at First Ever International Documentary Film Festival on Cancer Elbit Imaging Ltd. Announces Second Quarter Results for 2008 New approach, old drug show promise against hepatitis C, Stanford research shows Fish Oil Supplements Help With Heart Failure

Sugita Aneurysm Clip J-Shaped (M)

Sugita Aneurysm Clip 1/4 Cvd. (L)

Sugita Aneurysm Clip 45 Angled (L)

Sugita Aneurysm Clip L-Shaped (S)

Medicine Products:

Sugita Aneurysm Clip J-Shaped (M)Sugita Aneurysm Clip 1/4 Cvd. (L)Sugita Aneurysm Clip 45 Angled (L)Sugita Aneurysm Clip L-Shaped (S)

PDI Reports 2009 Third Quarter Financi...(er 2009 For the quarter ended Septe...),Health